Uroplasty (UPI) Receiving Somewhat Favorable News Coverage, Report Finds

News headlines about Uroplasty (NASDAQ:UPI) have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Uroplasty earned a news impact score of 0.01 on Accern’s scale. Accern also assigned media headlines about the medical device company an impact score of 45.2263274617841 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Uroplasty (NASDAQ UPI) remained flat at $$1.22 during mid-day trading on Wednesday. The firm has a market cap of $27.68, a P/E ratio of -4.07 and a beta of -1.26. Uroplasty has a 1-year low of $1.05 and a 1-year high of $4.05.

TRADEMARK VIOLATION NOTICE: “Uroplasty (UPI) Receiving Somewhat Favorable News Coverage, Report Finds” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/21/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-uroplasty-upi-stock-price.html.

Uroplasty Company Profile

Cogentix Medical, Inc (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover.

Insider Buying and Selling by Quarter for Uroplasty (NASDAQ:UPI)

Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply